Skip to main content

Advertisement

SpringerLink
Log in

18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

It remains controversial whether positron emission tomography (PET) with 2-deoxy-2-[F-18]fluoro-d-glucose (F-18-FDG) can differentiate between benign and malignant musculoskeletal tumors. To uncover the mechanism of F-18-FDG accumulations, we analyzed the correlation between the F-18-FDG accumulation and the expression of glucose transporter 1 (Glut-1) and hexokinase II (HK-II) in benign and malignant musculoskeletal tumors.

Methods

The maximum standardized uptake values (SUVmax) of F-18-FDG in 24 benign and 26 malignant musculoskeletal tumors were compared with the histologic malignancies, and the expression of Glut-1 and HK-II was analyzed by immunohistochemistry.

Results

The SUVmax for malignant tumors (6.33 ± 4.79) was significantly higher than those with benign tumors (3.47 ± 3.12, P < 0.01). The expression of Glut-1 was high in 12 patients (all malignant) and low in 38 patients (24 benign and 14 malignant), and the expression of HK-II was high in 36 patients (11 benign and 25 malignant) and low in 14 patients (13 benign and 1 malignant). Cases with high expression of Glut-1 and HK-II at immunohistochemistry showed a higher SUVmax than those with low expression (Glut-1 8.03 ± 5.10 and 3.98 ± 3.53, P < 0.01; HK-II 5.73 ± 4.49 and 2.99 ± 3.02, P < 0.01). No significant dividing threshold of the SUVmax of F-18 FDG was found for the differential diagnosis between benign and malignant tumors or for the expression of Glut-1 and HK-II.

Conclusions

The limited capability of F-18 FDG-PET in the differential diagnosis of musculoskeletal tumors is owing partly to the various levels of Glut-1 and HK-II expression in individual tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–648.

    PubMed  CAS  Google Scholar 

  2. Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000;126:560–574.

    Article  PubMed  CAS  Google Scholar 

  3. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002;29:443–453.

    Article  PubMed  CAS  Google Scholar 

  4. Waki A, Fujibayashi Y, Yokoyama A. Recent advances in the analyses of the characteristics of tumors on FDG uptake. Nucl Med Biol 1998;25:589–592.

    Article  PubMed  CAS  Google Scholar 

  5. Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-d-glucose. Radiology 1996;200:243–247.

    PubMed  CAS  Google Scholar 

  6. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000;41:1695–1701.

    PubMed  CAS  Google Scholar 

  7. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510–518.

    PubMed  Google Scholar 

  8. Watson RT, Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 2001;56:175–193.

    Article  PubMed  CAS  Google Scholar 

  9. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29:339–343.

    Article  PubMed  CAS  Google Scholar 

  10. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369–379.

    Article  PubMed  CAS  Google Scholar 

  11. Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, et al. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 2005;52:486–490.

    PubMed  CAS  Google Scholar 

  12. Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–29.

    PubMed  CAS  Google Scholar 

  13. Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18) Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279–1287.

    PubMed  CAS  Google Scholar 

  14. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001;219:774–777.

    PubMed  CAS  Google Scholar 

  15. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173–180.

    PubMed  CAS  Google Scholar 

  16. Lewis WH. The vascular pattern of tumors. Bull Johns Hopkins Hosp 1927;41:156–162.

    Google Scholar 

  17. Sandison JC. Observations on the growth of blood vessels as seen in the transparent chamber introduced into the rabbit’s ear. Am J Anat 1928;41:475–496.

    Article  Google Scholar 

  18. Underwood JC, Carr I. The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma. J Pathol 1972;107:157–166.

    Article  PubMed  CAS  Google Scholar 

  19. Heuser LS, Miller FN. Differential macromolecular leakage from the vasculature of tumors. Cancer 1986;57:461–464.

    Article  PubMed  CAS  Google Scholar 

  20. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95–109.

    PubMed  CAS  Google Scholar 

  21. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003;3:319–328.

    Article  PubMed  CAS  Google Scholar 

  22. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271–284.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

    Kenichiro Hamada

  2. Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan

    Kenichiro Hamada, Ichiro Higuchi & Jun Hatazawa

  3. Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari, Osaka, 537-8511, Japan

    Yasuhiko Tomita

  4. Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan

    Ying Qiu, Binglin Zhang & Katsuyuki Aozasa

  5. Department of Orthopedic Surgery, Osaka National Hospital, Osaka, Japan

    Takafumi Ueda

  6. Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

    Akira Myoui & Hideki Yoshikawa

Authors
  1. Kenichiro Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhiko Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Binglin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takafumi Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Myoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ichiro Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuyuki Aozasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jun Hatazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhiko Tomita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamada, K., Tomita, Y., Qiu, Y. et al. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 22, 699–705 (2008). https://doi.org/10.1007/s12149-008-0173-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-008-0173-9

Keywords

Search

Navigation